FrancophonIA/ELRC3.0 huggingface dataset:
English: The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the prevention and treatment trials.
Slovenian: Vplive drugih sočasno danih zdravil na plazemske koncentracije raloksifena so ugotavljali v kliničnih raziskavah preventive in zdravljenja.
English: Plasma raloxifene concentrations were approximately 2.5-fold higher than in controls and correlated with bilirubin concentrations.
Slovenian: Plazemske koncentracije raloksifena so bile približno 2,5-krat višje kot plazemske koncentracije pri preiskovankah iz kontrolne skupine in so bile v korelaciji s koncentracijami bilirubina.
English: An effect on non-vertebral fractures has not been demonstrated.
Slovenian: Vpliva na nevretenčne zlome niso dokazali.
English: Raloxifene should not be co-administered with cholestyramine (or other anion exchange resins), which significantly reduces the absorption and enterohepatic cycling of raloxifene.
Slovenian: Raloksifena ne smemo dajati sočasno s holestiraminom (ali drugimi anionskimi izmenjevalnimi smolami), saj ta pomembno zmanjša absorpcijo in enterohepatično cirkulacijo raloksifena.
English: In children, symptoms of accidental overdose included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase.
Slovenian: Simptomi naključnega prevelikega odmerjanja pri otrocih so vključevali ataksijo, omotico, bruhanje, izpuščaj, drisko, tresenje in rdečico ter zvišanje alkalne fosfataze.
English: If you take more Optruma than you should you could have leg cramps and dizziness.
Slovenian: Če ste vzeli večji odmerek zdravila Optruma, kot bi smeli, se pri vas lahko pojavijo krči v nogah ali omotica.
English: In a 21-month carcinogenicity study in mice, there was an increased incidence of testicular interstitial cell tumours and prostatic adenomas and adenocarcinomas in males given 41 or 210 mg/kg, and prostatic leiomyoblastoma in males given 210 mg/kg.
Slovenian: V 21-mesečni raziskavi kancerogenosti na miših so ugotavljali povečano incidenco tumorjev testisa, ki so izvirali iz intersticijskih celic, adenomov prostate in adenokarcinomov pri samcih, ki so prejemali odmerke 41 ali 210 mg/kg, ter leiomioblastoma prostate pri samcih, ki so prejemali odmerke 210 mg/kg.
English: Therefore, Optruma should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed.
Slovenian: Zdravilo Optruma se za zdravljenje in preprečevanje osteoporoze lahko uporablja le po zaključenem zdravljenju raka dojke, vključno z vso spremljajočo terapijo.
English: In rare cases, blood levels of liver enzymes may increase during treatment with Optruma.
Slovenian: V redkih primerih se lahko med zdravljenjem z zdravilom Optruma zvišajo koncentracije jetrnih encimov v krvi.
English: The dose is one tablet a day.
Slovenian: Priporočen odmerek je ena tableta na dan, zaužita peroralno.
English: In the RUTH study, raloxifene did not affect the incidence of stroke, compared to placebo.
Slovenian: V študiji RUTH raloksifen ni imel vpliva na pogostnost kapi, v primerjavi s placebom.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Slovenian: Tega zdravila ne smejo uporabljati pacientke z redkimi podedovanimi težavami intolerance za galaktozo, s pomanjkanjem Lapp laktaze ali malabsorbcijo glukoze-galaktoze.
English: Results from single oral doses of raloxifene predict multiple dose pharmacokinetics.
Slovenian: Rezultati meritev po dajanju enega samega peroralnega odmerka raloksifena napovedujejo farmakokinetiko več odmerkov.
English: Other risk factors which may lead to the development of osteoporosis include early menopause; osteopenia (at least 1 SD below peak bone mass); thin body build; Caucasian or Asian ethnic origin; and a family history of osteoporosis.
Slovenian: Drugi dejavniki tveganja, ki lahko vodijo do nastanka osteoporoze, so tudi zgodnja menopavza, osteopenija (najmanj 1 SD pod maksimalno kostno maso), šibkejša telesna konstitucija, bela ali azijska rasa ter osteoporoza v družini.
English: However, since the overall extent of absorption and the elimination rate of raloxifene are not affected, raloxifene can be concurrently administered with ampicillin.
Slovenian: Ker pa to ne vpliva na celotni obseg absorpcije in ne na hitrost izločanja raloksifena iz telesa, lahko raloksifen uporabljamo hkrati z ampicilinom.
English: България ТП "Ели Лили Недерланд" Б.В.
Slovenian: ТП "Ели Лили Недерланд" Б.В.
English: • If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment or cholestatic jaundice).
Slovenian: • Če imate bolezen jeter (jetrne bolezni so na primer ciroza, blaga okvara jeter ali holestatska zlatenica).
English: Raloxifene is metabolised primarily in the liver.
Slovenian: Raloksifen se presnavlja predvsem v jetrih.
English: In rabbits, abortion and a low rate of ventricular septal defects (≥ 0.1 mg/kg) and hydrocephaly (≥ 10 mg/kg) were seen.
Slovenian: Pri kuncih so opažali splave, majhno pogostnost defektov ventrikularnega septuma (≥ 0,1 mg/kg) in hidrocefalijo (≥
English: Very common: Flu syndrome Common: Peripheral oedema
Slovenian: Splošne težave in spremembe na mestu aplikacije Zelo pogosti: sindrom gripe Pogosti: periferni edem
English: There is no specific antidote for raloxifene hydrochloride.
Slovenian: Specifičnega antidota za raloksifenijev klorid ne poznamo.
English: These observations support the conclusion that raloxifene has no intrinsic oestrogen agonist activity in breast tissue.
Slovenian: Ta opažanja podpirajo sklep, da raloksifen sam po sebi ne deluje kot agonist estrogena v tkivu dojke.
English: Optruma therapy for 8 years did not significantly affect the risk of cardiovascular events in patients enrolled in the osteoporosis treatment study.
Slovenian: Osemletno zdravljenje z zdravilom Optruma pri bolnicah, vključenih v študijo zdravljenja osteoporoze, ni značilno vplivalo na tveganje za srčnožilne dogodke.
English: The majority of side effects seen with Optruma have been mild.
Slovenian: Neželeni učinki, ki so jih opažali pri zdravilu Optruma, so bili večinoma blagi.
English: When given during the preimplantation period, raloxifene delayed and disrupted embryo implantation resulting in prolonged gestation and reduced litter size but development of offspring to weaning was not affected.
Slovenian: Če so raloksifen dali v času pred implantacijo, je zakasnil implatancijo embrija, povzročil motnje pri implatanciji in posledično podaljšano gestacijo ter zmanjšanje števila mladičev, vendar pa razvoj mladičev do odstavitve ni bil moten.
English: From the 4th to the 8th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin D supplementation.
Slovenian: Od četrtega do osmega leta zdravljenja so bolnicam dovolili sočasno jemanje difosfonatov, kalcitonina in fluoridov in vse bolnice iz te raziskave so jemale dodatke kalcija in vitamina D. V študiji RUTH so kot sekundarni cilj zbirali podatke o celotnih kliničnih zlomih.
English: INFORMATION IN BRAILLE
Slovenian: PODATKI V BRAILLOVI PISAVI Optruma
English: In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, overall mortality, including overall cardiovascular mortality, or stroke, compared to placebo.
Slovenian: V študiji pri postmenopavzalnih ženskah z dokumentirano koronarno srčno boleznijo ali z večjim tveganjem za koronarne dogodke raloksifen v primerjavi s placebom ni vplival na incidenco miokardnega infarkta, hospitaliziranega akutnega koronarnega sindroma, celotne smrtnosti, vključno s celotno srčnožilno smrtnostjo, ali kapi.
English: In postmenopausal women with osteoporosis, Optruma reduces the incidence of vertebral fractures, preserves bone mass and increases bone mineral density (BMD).
Slovenian: Pri ženskah po menopavzi, ki imajo osteoporozo, zdravilo Optruma zmanjša incidenco zlomov vretenc, ohrani kostno maso in poveča mineralno kostno gostoto (BMD - bone mineral density).
English: Superficial vein thrombophlebitis occurred in a frequency of 1 % in the raloxifene group and 0.6 % in the placebo group.
Slovenian: Pojavnost površinskega venskega tromboflebitisa je bila 1 % v skupini raloksifena in 0,6 % v skupini placeba.
English: The time to reach average maximum plasma concentration and bioavailability are functions of systemic interconversion and enterohepatic cycling of raloxifene and its glucuronide metabolites.
Slovenian: Čas, potreben, da raloksifen doseže povprečne vrednosti maksimalne plazemske koncentracije in biološke uporabnosti, je odvisen od sistemske interkonverzije ter enterohepatične cirkulacije raloksifena in njegovih glukuronidnih presnovkov.
English: Flu syndrome was reported by 16.2 % of Optruma treated patients and 14.0 % of placebo treated patients.
Slovenian: O sindromu gripe so poročali pri 16,2 % bolnic, zdravljenih z zdravilom Optruma , in pri 14,0 % bolnic, ki so jemale placebo.
English: Across all placebo-controlled trials, Optruma was indistinguishable from placebo with regard to frequency and severity of breast symptoms (no swelling, tenderness and breast pain).
Slovenian: V vseh s placebom nadzorovanih preskušanjih vpliva zdravljenja z zdravilom Optruma ni bilo mogoče razlikovati od vpliva placeba, kar zadeva pogostnost in stopnjo simptomov v zvezi z dojkami (brez nabrekanja, občutljivosti in bolečin v dojkah).
English: Optruma should not be used in patients with severe renal impairment (see section 4.3).
Slovenian: Zdravila Optruma ne smemo uporabljati pri bolnikih s hudo ledvično okvaro (glejte poglavje 4.3).
English: Tablet coating: Titanium dioxide (E 171), polysorbate 80, hypromellose, macrogol 400, carnauba wax.
Slovenian: Obloga tablete: titanov dioksid (E171), polisorbat 80, hipromeloza, makrogol 400, karnauba vosek.
English: ANNEX II A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
English: Endometrial thickness measurements in Optruma treated women were not different from baseline after 4 years of therapy.
Slovenian: Meritve debeline endometrija pri ženskah, ki so bile zdravljene z zdravilom Optruma, se po 4 letih terapije niso razlikovale od začetnih vrednosti.
English: The safety of Optruma in patients with breast cancer has not been adequately studied.
Slovenian: Zadostnih študij o varnosti zdravila Optruma pri bolnicah z rakom dojke ni.
English: The decrease in oestrogen availability which occurs at menopause, leads to marked increases in bone resorption, bone loss and risk of fracture.
Slovenian: Zmanjšanje razpoložljivosti estrogena, ki nastopi ob menopavzi, povzroči znatno povečanje resorpcije kosti, izgubo kostne mase in povečanje nevarnosti za zlome kosti.
English: Raloxifene comprises less than 1 % of the combined concentrations of raloxifene and the glucuronide metabolites.
Slovenian: Količina samega raloksifena je manjša od 1 % celotnega seštevka koncentracij raloksifena in njegovih glukuronidnih presnovkov.
English: This binding results in differential expression of multiple oestrogen-regulated genes in different tissues.
Slovenian: Vezava na estrogenske receptorje povzroči različno ekspresijo več estrogensko reguliranih genov v različnih tkivih.
English: Clinical trials showed that a 60 mg daily dose of Optruma significantly decreased total cholesterol (3 to 6 %), and LDL cholesterol (4 to 10 %).
Slovenian: b) Vplivi na presnovo lipidov in srčnožilno tveganje Klinične raziskave so pokazala, da dnevni odmerek zdravila Optruma 60 mg značilno zniža vrednosti skupnega holesterola (3 do 6 %) in LDL holesterola (4 do 10 %).
English: Do not use after the expiry date which is stated on the pack after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: In a study of 10,101 postmenopausal women with documented coronary heart disease or at increased risk for coronary events (RUTH), the occurrence of vasodilatation (hot flushes) was 7.8 % in the raloxifene-treated patients and 4.7 % in the placebo-treated patients.
Slovenian: V študiji 10101 postmenopavzalnih žensk z dokazano koronarno srčno boleznijo ali s povečanim tveganjem za koronarne dogodke (RUTH), je bila pojavnost vazodilatacije (navalov vročine) pri bolnicah zdravljenih z raloksifenom 7,8 % in 4,7 % pri bolnicah, ki so jemale placebo.
English: Tablet Core: Povidone, polysorbate 80, anhydrous lactose, lactose monohydrate, crospovidone, magnesium stearate.
Slovenian: Jedro tablete: povidon, polisorbat 80, brezvodna laktoza, laktoza monohidrat, krospovidon, magnezijev stearat.
English: Systemic exposure (AUC) of raloxifene in this group was approximately 400 times that in postmenopausal women administered a 60 mg dose.
Slovenian: Sistemska izpostavljenost raloksifenu (AUC) v tej skupini preiskovanih podgan je bila približno 400-krat večja od vrednosti za ženske po menopavzi,
English: Optruma produced significant increases in bone density of hip and spine as well as total body mineral mass compared to placebo.
Slovenian: Zdravilo Optruma je povzročilo značilno povečanje kostne gostote v kolku in hrbtenici, pa tudi značilno povečanje celotne kostne mineralne mase v telesu v primerjavi s placebom.
English: Raloxifene does not affect the steady-state AUC of digoxin.
Slovenian: Raloksifen ne vpliva na AUC v stanju dinamičnega ravnovesja za digoksin.
English: In the RUTH study, peripheral oedema occurred in 14.1 % of the raloxifene-treated patients and 11.7 % of the placebo-treated patients, which was statistically significant.
Slovenian: V študiji RUTH se je periferni edem pojavljal pri 14,1 % bolnic zdravljenih z raloksifenom in 11,7 % bolnic, ki so jemale placebo, kar je bilo statistično značilno.
English: Across all placebo-controlled clinical trials of raloxifene in osteoporosis, venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis occurred at a frequency of approximately 0.8 % or 3.22 cases per 1,000 patient years.
Slovenian: V vseh kliničnih preskušanjih raloksifena pri osteoporozi, nadzorovanih s placebom, so se venski tromboembolični zapleti, vključno s trombozo globokih ven, pljučnimi embolijami in trombozo retinalnih ven, pojavljali v približno 0,8 % ali 3,22 primerih na 1.000 bolniških let.
English: Raloxifene undergoes extensive first pass metabolism to the glucuronide conjugates: raloxifene-4'glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4′-diglucuronide.
Slovenian: Raloksifen se že pri prvem prehodu skozi jetra v veliki meri presnovi v glukuronidne konjugate: raloksifen-4'-glukuronid, raloksifen-6-glukuronid in raloksifen-6,4'-diglukuronid.
English: The incidence of stroke mortality was 2.2 per 1000 women per year for raloxifene versus 1.5 per 1000 women per year for placebo (see section 4.8).
Slovenian: Incidenca smrtnosti zaradi kapi je bila 2,2 na 1000 žensk na leto za raloksifen proti 1,5 na 1000 žensk na leto za placebo (glejte poglavje 4.8).
English: Raloxifene decreases resorption of bone; this effect on bone is manifested as reductions in the serum and urine levels of bone turnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in BMD and decreases in the incidence of fractures.
Slovenian: Ta učinek na kosti se kaže v obliki znižanja koncentracije indikatorjev kostne presnove v serumu in urinu, zmanjšanja resorpcije kosti, ugotovljenega na podlagi raziskav kinetike radiološko označenega kalcija, povečanja BMD in v obliki zmanjšanja incidence zlomov.
English: In the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37 % decreased and 63 % increased; and for the total hip 29 % decreased and 71 % increased.
Slovenian: V preskušanjih preventive osteoporoze z zdravilom Optruma so bili odstotki preiskovank, pri katerih so ugotovili povečanje ali zmanjšanje BMD med terapijo z raloksifenom, naslednji: za hrbtenico so pri 37 % preiskovank ugotovili zmanjšanje in pri 63 % povečanje BMD; za celoten kolk so pri 29 % ugotovili zmanjšanje in pri 71 % povečanje BMD.
English: Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.
Slovenian: Raloksifen ne vpliva na farmakokinetiko metilprednizolona, ki ga bolnici damo v enem samem odmerku.
English: Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines.
Slovenian: nesteroidna protivnetna zdravila (kakor so npr. acetilsalicilna kislina, ibuprofen in naproksen), peroralni antibiotiki, antagonisti H1 receptorjev, antagonisti H2 receptorjev in benzodiazepini.
English: The most common side effects (affects more than 1 user in 10) are:
Slovenian: Najpogostejši neželeni učinki (prizadanejo več kot 1 bolnico od 10 bolnic) so:
English: Hepatic insufficiency - The pharmacokinetics of a single dose of raloxifene in patients with cirrhosis and mild hepatic impairment (Child-Pugh class A) have been compared to that in healthy individuals.
Slovenian: Jetrna insuficienca - Farmakokinetiko enkratnega odmerka raloksifena pri bolnicah s cirozo in blago jetrno okvaro (razred A po Child-Pughu) so primerjali s farmakokinetiko enega odmerka raloksifena pri zdravih preiskovankah.
English: After 3 years of treatment, at least a 5 mm increase in endometrial thickness, assessed with transvaginal ultrasound, was observed in 1.9 % of the 211 women treated with raloxifene 60 mg/day compared to 1.8 % of the 219 women who received placebo.
Slovenian: Pri 1,9 % od 211 žensk, ki so jih zdravili z raloksifenom v odmerku 60 mg na dan, so po 3 letih zdravljenja ugotovili najmanj 5-milimetrsko povečanje debeline endometrija, kar so ugotavljali s transvaginalnim ultrazvokom, v primerjavi z 1,8 % od 219 žensk, ki so prejemale placebo.
English: Patients with this medical history should have serum triglycerides monitored when taking raloxifene.
Slovenian: Pri teh bolnicah je treba pri jemanju raloksifena spremljati serumske trigliceride.
English: Similarly, in the RUTH study, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, stroke or overall mortality, including overall cardiovascular mortality, compared to placebo (for the increase in risk of fatal stroke see section 4.4).
Slovenian: raloksifen v primerjavi s placebom ni vplival na incidenco miokardnega infarkta, hospitalizacije akutnega koronarnega sindroma, kapi ali celokupno smrtnost, vključno s celokupno kardiovaskularno smrtnostjo (za povečanje tveganja smrtne kapi glejte poglavje 4.4).
English: Optruma lowers total cholesterol and LDL ("bad") cholesterol.
Slovenian: Zdravilo Optruma znižuje vrednost celokupnega holesterola in LDL ('slabega') holesterola.
English: Optruma contains lactose.
Slovenian: Zdravilo Optruma vsebuje laktozo.
English: Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in Optruma patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % Optruma and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for Optruma and 7.1 % placebo).
Slovenian: V primerjavi z bolnicami, ki so prejemale placebo, je bila pogostnost pojavov vazodilatacije (navali vročine) zmerno povečana pri bolnicah, zdravljenih z zdravilom Optruma (pri kliničnih preskušanjih za preventivo osteoporoze, trajanje menopavze 2 do 8 let - 24,3 % pri zdravilu Optruma in 18,2 % pri placebu; pri kliničnih raziskavah za zdravljenje osteoporoze, povprečna starost 66 let - 10,6 % pri zdravilu Optruma in 7,1 % pri placebu).
English: How to take Optruma
Slovenian: Kako jemati zdravilo Optruma
English: There was no difference between Optruma and placebo treated women in the incidences of vaginal bleeding (spotting) or vaginal discharge.
Slovenian: Tudi ni bilo razlike med ženskami, zdravljenimi z zdravilomOptruma, in tistimi, ki so prejemale placebo, kar zadeva incidenco vaginalne krvavitve (krvavega izcedka) ali izcedka iz nožnice.
English: Women with the highest baseline cholesterol levels had the greatest decreases.
Slovenian: To znižanje je bilo največje pri ženskah z najvišjimi začetnimi vrednostmi holesterola.
English: How Optruma works
Slovenian: Kako zdravilo Optruma deluje
English: A reduction in the risk of hip fractures has not been shown.
Slovenian: Raziskave niso dokazale zmanjšanja tveganja za zlom kolka.
English: Optruma does not treat postmenopausal symptoms, such as hot flushes.
Slovenian: Zdravilo Optruma ne zdravi postmenopavzalnih simptomov, kakor so navali vročine.
English: When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).
Slovenian: Ko se zdravnik pri posamezni ženski po menopavzi odloča med zdravilom Optruma ali drugimi oblikami zdravljenja, vključno z estrogeni, mora pri tem upoštevati simptome menopavze pri njej in učinke zdravila na tkivo maternice in dojke ter pretehtati koristi in tveganja za srčnožilna obolenja
English: This was peripheral oedema, which occurred in the prevention population at an incidence of 3.1 % for Optruma and 1.9 % for placebo; and in the treatment population occurred at an incidence of 7.1 % for Optruma and 6.1 % for placebo.
Slovenian: To je bil periferni edem, ki se je v skupini, pri kateri so raloksifen uporabljali za preventivo, pojavljal z incidenco 3,1 % za zdravilo Optruma in 1,9 % za placebo ter v skupini, pri kateri so raloksifen uporabljali za zdravljenje, z incidenco 7,1 % za zdravilo Optruma in 6,1 % za placebo.
English: Raloxifene's biological actions, like those of oestrogen, are mediated through high affinity binding to oestrogen receptors and regulation of gene expression.
Slovenian: Podobno kot velja za učinke estrogena, raloksifen biološko deluje preko vezave z veliko afiniteto na estrogenske receptorje ter regulacije genske ekspresije.
English: In a study (RUTH) of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an additional adverse reaction of cholelithiasis occurred in 3.3 % of patients treated with raloxifene and 2.6 % of patients treated with placebo.
Slovenian: V študiji (RUTH) postmenopavzalnih žensk z dokazano koronarno srčno boleznijo ali s povečanim tveganjem za koronarne dogodke se je pojavil dodatni neželeni učinek, holelitiaza pri 3,3 % bolnic zdravljenih z raloksifenom in 2,6 % bolnic, ki so jemale placebo.
English: Safety information following 3 years of raloxifene treatment suggests that raloxifene treatment does not increase pelvic floor relaxation and pelvic floor surgery.
Slovenian: Podatki o varnosti po 3 letih zdravljenja z raloksifenom kažejo, da slednje ne poveča pojavnosti popuščanja medeničnega dna in operacijskih posegov na medeničnem dnu.
English: Very common: Vasodilation (hot flushes) Uncommon: Venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis, Arterial thromboembolic reactions a
Slovenian: Zelo pogosti: vazodilatacija (navali vročine) Občasni: venski tromboembolični zapleti, vključno z globoko vensko trombozo, pljučnimi embolijami, trombozo mrežničnih ven, tromboflebitis povrhnjih ven, arterijske tromboembolične reakcijea
English: There was no difference between treatment groups in the incidence of new nonvertebral fractures.
Slovenian: incidenci novih nevretenčnih zlomov ni bilo razlik med zdravljenimi skupinami.